BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.82 USD
+0.01 (1.26%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.82 0.00 (-0.07%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BLRX 0.82 +0.01(1.26%)
Will BLRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BLRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for BLRX
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Buy Rating Affirmed for Bioline RX on Promising Motixafortide Trial Results
Biotech Alert: Searches spiking for these stocks today
BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide